{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sex+Chromosome+Abnormalities&page=3", "query": { "condition": "Sex Chromosome Abnormalities", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 155, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sex+Chromosome+Abnormalities&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sex+Chromosome+Abnormalities&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T05:40:42.784Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03109756", "title": "Single Dose Pharmacokinetic (PK) Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Angelman Syndrome", "Fragile X Syndrome" ], "interventions": [ { "name": "OV101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ovid Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "13 Years to 17 Years" }, "enrollment_count": 12, "start_date": "2017-04-03", "completion_date": "2017-11-28", "has_results": false, "last_update_posted_date": "2017-11-30", "last_synced_at": "2026-10-01T05:40:42.784Z", "location_count": 2, "location_summary": "Chicago, Illinois • Nashville, Tennessee", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03109756" }, { "nct_id": "NCT06560242", "title": "Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- Infant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Fragile X Syndrome" ], "interventions": [ { "name": "Speech discrimination", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": "26 Months", "sex": "ALL", "summary": "6 Months to 26 Months" }, "enrollment_count": 30, "start_date": "2022-10-31", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-01T05:40:42.784Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06560242" }, { "nct_id": "NCT07643896", "title": "The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pregnant Individuals", "Aneuploidy", "Down Syndrome (Trisomy 21)", "22q11.2 Deletion Syndrome", "Trisomy 13", "Trisomy 18", "Sex Chromosome Abnormalities" ], "interventions": [], "intervention_types": [], "sponsor": "BillionToOne Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 1000, "start_date": "2026-01-10", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-01T05:40:42.784Z", "location_count": 6, "location_summary": "Phoenix, Arizona • West Covina, California • Sarasota, Florida + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "West Covina", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07643896" }, { "nct_id": "NCT01725152", "title": "Ganaxolone Treatment in Children With Fragile X Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fragile x Syndrome" ], "interventions": [ { "name": "Ganaxolone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marinus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 59, "start_date": "2012-11", "completion_date": "2016-11-01", "has_results": true, "last_update_posted_date": "2023-04-10", "last_synced_at": "2026-10-01T05:40:42.784Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01725152" }, { "nct_id": "NCT04823052", "title": "Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fragile X Syndrome" ], "interventions": [ { "name": "Sulindac (HLX-0201), dose strength 1", "type": "DRUG" }, { "name": "Sulindac (HLX-0201), dose strength 2", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Gaboxadol (HLX-0206)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Healx Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "40 Years", "sex": "MALE", "summary": "13 Years to 40 Years · Male only" }, "enrollment_count": 0, "start_date": "2022-05-25", "completion_date": "2022-10-19", "has_results": false, "last_update_posted_date": "2022-12-08", "last_synced_at": "2026-10-01T05:40:42.784Z", "location_count": 7, "location_summary": "Aurora, Colorado • Miami, Florida • Atlanta, Georgia + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04823052" }, { "nct_id": "NCT05548881", "title": "Implications of Maternal 45,X Mosaicism as a Secondary Genomic Finding Following Cell-Free DNA Sequencing During Pregnancy: A Deep Phenotype Study", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cardiovascular Phenotype", "Metabolic Phenotype", "Hypertensive Disease", "Psychological Phenotype", "Audio" ], "interventions": [], "intervention_types": [], "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 0, "start_date": "2025-04-01", "completion_date": "2025-04-01", "has_results": false, "last_update_posted_date": "2025-04-02", "last_synced_at": "2026-10-01T05:40:42.784Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05548881" }, { "nct_id": "NCT00890747", "title": "Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Acute Undifferentiated Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Grade III Lymphomatoid Granulomatosis", "Adult Langerhans Cell Histiocytosis", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Aggressive NK-cell Leukemia", "AIDS-related Diffuse Large Cell Lymphoma", "AIDS-related Diffuse Mixed Cell Lymphoma", "AIDS-related Diffuse Small Cleaved Cell Lymphoma", "AIDS-related Immunoblastic Large Cell Lymphoma", "AIDS-related Lymphoblastic Lymphoma", "AIDS-related Malignancies", "AIDS-related Small Noncleaved Cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Chronic Eosinophilic Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Clear Cell Renal Cell Carcinoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "de Novo Myelodysplastic Syndromes", "Essential Thrombocythemia", "Extramedullary Plasmacytoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "HIV Infection", "HIV-associated Hodgkin Lymphoma", "Intraocular Lymphoma", "Isolated Plasmacytoma of Bone", "Light Chain Deposition Disease", "Mast Cell Leukemia", "Myelodysplastic Syndrome With Isolated Del(5q)", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Myeloid/NK-cell Acute Leukemia", "Nodal Marginal Zone B-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Osteolytic Lesions of Multiple Myeloma", "Peripheral T-cell Lymphoma", "Plasma Cell Neoplasm", "Polycythemia Vera", "Post-transplant Lymphoproliferative Disorder", "Previously Treated Myelodysplastic Syndromes", "Primary Myelofibrosis", "Primary Systemic Amyloidosis", "Progressive Hairy Cell Leukemia, Initial Treatment", "Prolymphocytic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Renal Cell Cancer", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Stage IV Renal Cell Cancer", "T-cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "sunitinib malate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2009-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-03-17", "last_synced_at": "2026-10-01T05:40:42.784Z", "location_count": 11, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00890747" }, { "nct_id": "NCT02278874", "title": "High Risk Multiple Gestation Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Trisomy 13", "Trisomy 18", "Trisomy 21", "Sex Chromosome Abnormalities" ], "interventions": [], "intervention_types": [], "sponsor": "Natera, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2014-08", "completion_date": "2019-03", "has_results": false, "last_update_posted_date": "2019-06-13", "last_synced_at": "2026-10-01T05:40:42.784Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Glen Cove, New York • New York, New York + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Glen Cove", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02278874" }, { "nct_id": "NCT01574781", "title": "Non-invasive Prenatal Diagnostic Validation Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chromosome 13 Aneuploidy", "Chromosome 18 Aneuploidy", "Chromosome 21 Aneuploidy", "Sex Chromosome Aberrations", "Other Microdeletions" ], "interventions": [ { "name": "Blood draw", "type": "PROCEDURE" }, { "name": "Cheek swab/Saliva Sampling", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Natera, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1781, "start_date": "2011-09", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2013-07-02", "last_synced_at": "2026-10-01T05:40:42.784Z", "location_count": 1, "location_summary": "Redwood City, California", "locations": [ { "city": "Redwood City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01574781" }, { "nct_id": "NCT01367834", "title": "Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Turner Syndrome" ], "interventions": [ { "name": "somatotropin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rebecca Knickmeyer Santelli, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "11 Months", "maximum_age": "13 Months", "sex": "FEMALE", "summary": "11 Months to 13 Months · Female only" }, "enrollment_count": 17, "start_date": "2010-05", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2017-03-24", "last_synced_at": "2026-10-01T05:40:42.784Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01367834" } ] }